Maraviroc Attenuates Trauma-Hemorrhage-Induced Hepatic Injury through PPAR Gamma-Dependent Pathway in Rats

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Liu, Fu Chao ^a,b   Tsai, Yung Fong ^a,b,c   Yu, Huang Ping ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MARAVIROC; MYELOPEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; LIVER HEMORRHAGE; LIVER INJURY; LIVER PROTECTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HEMORRHAGE; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LIVER; MALE; PEROXIDASE; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; TRIAZOLES;

EID: 84885817150     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078861     Document Type: Article

References (34)

1. Liu FC, Yu HP, Hwang TL, Tsai YF, (2012) Protective effect of tropisetron on rodent hepatic injury after trauma-hemorrhagic shock through P38 MAPK-dependent hemeoxygenase-1 expression. PLOS ONE 7: e53203. doi:10.1371/journal.pone.0053203. PubMed: 23285267.
2. Yu HP, Yang SC, Lau YT, Hwang TL, (2010) Role of Akt-dependent up-regulation of hemeoxygenase-1 in resveratrol-mediated attenuation of hepatic injury after trauma hemorrhage. Surgery 148: 103-109. doi:10.1016/j.surg.2009.12.008. PubMed: 20117814.
3. Angele MK, Schneider CP, Chaudry IH, (2008) Bench-to-bedside review: latest results in hemorrhagic shock. Crit Care 12: 218. doi:10.1186/cc6439. PubMed: 18638356.
4. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W, (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45: 120-159. doi:10.1016/j.plipres.2005.12.002. PubMed: 16476485.
5. Chinetti G, Fruchart JC, Staels B, (2000) Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49: 497-505. doi:10.1007/s000110050622. PubMed: 11089900.
6. Kuboki S, Shin T, Huber N, Eismann T, Galloway E, et al. (2008) Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice. Hepatology 47: 215-224. PubMed: 18085707.
7. Akahori T, Sho M, Hamada K, Suzaki Y, Kuzumoto Y, et al. (2007) Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice. J Hepatol 47: 784-792. doi:10.1016/j.jhep.2007.07.030. PubMed: 17936399.
8. Abdelrahman M, Sivarajah A, Thiemermann C, (2005) Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 65: 772-781. doi:10.1016/j.cardiores.2004.12.008. PubMed: 15721857.
9. Shimizu T, Szalay L, Hsieh YC, Suzuki T, Choudhry MA, et al. (2006) A role of PPAR-gamma in androstenediol-mediated salutary effects on cardiac function following trauma-hemorrhage. Ann Surg 244: 131-138. doi:10.1097/01.sla.0000217709.00863.82. PubMed: 16794398.
10. Zingarelli B, Hake PW, O'Connor M, Burroughs TJ, Wong HR, et al. (2009) Lung injury after hemorrhage is age dependent: role of peroxisome proliferator-activated receptor gamma. Crit Care Med 37: 1978-1987. doi:10.1097/CCM.0b013e31819feb4d. PubMed: 19384226.
11. Collin M, Abdelrahman M, Thiemermann C, (2004) Endogenous ligands of PPAR-gamma reduce the liver injury in haemorrhagic shock. Eur J Pharmacol 486: 233-235. doi:10.1016/j.ejphar.2003.12.032. PubMed: 14975712.
12. Reddy AT, Lakshmi SP, Kleinhenz JM, Sutliff RL, Hart CM, et al. (2012) Endothelial cell peroxisome proliferator-activated receptor gamma reduces endotoxemic pulmonary inflammation and injury. J Immunol 189: 5411-5420. doi:10.4049/jimmunol.1201487. PubMed: 23105142.
13. Napimoga MH, Vieira SM, Dal-Secco D, Freitas A, Souto FO, et al. (2008) Peroxisome proliferator-activated receptor-gamma ligand, 15-deoxy-Delta12,14-prostaglandin J2, reduces neutrophil migration via a nitric oxide pathway. J Immunol 180: 609-617. PubMed: 18097063.
14. Sharma R, Kaundal RK, Sharma SS, (2009) Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs. Pulm Pharmacol Ther 22: 183-189. doi:10.1016/j.pupt.2008.11.011. PubMed: 19073273.
15. Suzuki T, Kawasaki T, Choudhry MA, Chaudry IH, (2011) Role of PPARgamma in the salutary effects of 17beta-estradiol on Kupffer cell cytokine production following trauma-hemorrhage. J Cell Physiol 226: 205-211. doi:10.1002/jcp.22327. PubMed: 20665707.
16. Perry CM, (2010) Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. Drugs 70: 1189-1213. doi:10.2165/11203940-000000000-00000. PubMed: 20518583.
17. Kromdijk W, Huitema AD, Mulder JW, (2010) Treatment of HIV infection with the CCR5 antagonist maraviroc. Expert Opin Pharmacother 11: 1215-1223. doi:10.1517/14656561003801081. PubMed: 20402558.
18. Ochoa-Callejero L, Pérez-Martínez L, Rubio-Mediavilla S, Oteo JA, Martínez A, et al. (2013) Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLOS ONE 8: e53992. doi:10.1371/journal.pone.0053992. PubMed: 23326556.
19. Rossi R, Lichtner M, De RA, Sauzullo I, Mengoni F, et al. (2011) In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol 166: 184-190. doi:10.1111/j.1365-2249.2011.04409.x. PubMed: 21985364.
20. Lee YK, Choi DY, Jung YY, Yun YW, Lee BJ, et al. (2013) Decreased pain responses of C-C chemokine receptor 5 knockout mice to chemical or inflammatory stimuli. Neuropharmacology 67: 57-65. doi:10.1016/j.neuropharm.2012.10.030. PubMed: 23147416.
21. Li J, Chen G, Ye P, Wang S, Zhang K, et al. (2011) CCR5 blockade in combination with cyclosporine increased cardiac graft survival and generated alternatively activated macrophages in primates. J Immunol 186: 3753-3761. doi:10.4049/jimmunol.1002143. PubMed: 21307294.
22. Liu FC, Hwang TL, Lau YT, Yu HP, (2011) Mechanism of salutary effects of astringinin on rodent hepatic injury following trauma-hemorrhage: Akt-dependent hemeoxygenase-1 signaling pathways. PLOS ONE 6: e25907. doi:10.1371/journal.pone.0025907. PubMed: 22022464.
23. Yu HP, Hsieh PW, Chang YJ, Chung PJ, Kuo LM, et al. (2011) 2-(2-Fluorobenzamido)benzoate ethyl ester (EFB-1) inhibits superoxide production by human neutrophils and attenuates hemorrhagic shock-induced organ dysfunction in rats. Free Radic Biol Med 50: 1737-1748. doi:10.1016/j.freeradbiomed.2011.03.026. PubMed: 21457779.
24. Yu HP, Liu FC, Tsai YF, Hwang TL, (2013) Osthole attenuates hepatic injury in a rodent model of trauma-hemorrhage. PLOS ONE 8: e65916. doi:10.1371/journal.pone.0065916. PubMed: 23755293.
25. Ray N, (2009) Maraviroc in the treatment of HIV infection. Drugs Devel Ther 2: 151-161. PubMed: 19920903.
26. Lisi L, Tramutola A, De La, Navarra P, Dello RC (2012) Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120. J Neurochem 120: 106-114. doi:10.1111/j.1471-4159.2011.07549.x. PubMed: 22017448.
27. Capetti AF, Pocaterra D, Zucchi P, Carenzi L, Rizzardini G, (2010) Anti-inflammatory effect of maraviroc in an HIV-infected patient with concomitant myositis: a case report. J Int Assoc Physicians AIDS Care (Chic) 9: 201-202. doi:10.1177/1545109710372671.
28. Sperry JL, Friese RS, Frankel HL, West MA, Cuschieri J, et al. (2008) Male gender is associated with excessive IL-6 expression following severe injury. J Trauma 64: 572-578. doi:10.1097/TA.0b013e3181650fdf. PubMed: 18332795.
29. Shimizu T, Szalay L, Hsieh YC, Choudhry MA, Bland KI, et al. (2005) Salutary effects of androstenediol on hepatic function after trauma-hemorrhage are mediated via peroxisome proliferators-activated receptor gamma. Surgery 138: 204-211. doi:10.1016/j.surg.2005.03.017. PubMed: 16153428.
30. Ito H, Nakano A, Kinoshita M, Matsumori A, (2003) Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 83: 1715-1721. doi:10.1097/01.LAB.0000106724.29121.DA. PubMed: 14691289.
31. Reel B, Guzeloglu M, Bagriyanik A, Atmaca S, Aykut K, et al. (2013) The effects of PPAR-gamma agonist pioglitazone on renal ischemia/reperfusion injury in rats. J Surg Res 182: 176-184. doi:10.1016/j.jss.2012.08.020. PubMed: 22981741.
32. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R, (2008) PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 1244: 164-172. doi:10.1016/j.brainres.2008.09.074. PubMed: 18948087.
33. Jung Y, Song S, Choi C, (2008) Peroxisome proliferator activated receptor gamma agonists suppress TNFalpha-induced ICAM-1 expression by endothelial cells in a manner potentially dependent on inhibition of reactive oxygen species. Immunol Lett 117: 63-69. doi:10.1016/j.imlet.2007.12.002. PubMed: 18206249.
34. Collino M, Patel NS, Lawrence KM, Collin M, Latchman DS, et al. (2005) The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int 68: 529-536. doi:10.1111/j.1523-1755.2005.00430.x. PubMed: 16014029.